Navigation path

NM4TB


Tuberculosis

New Medicines for Tuberculosis
Framework programme:
6
Call:
3
Project number:
LSHP-CT-2006-018923
EC contribution:
€ 11,070,000
Duration:
60 months
Type:
IP
Starting date:
January 2006

Keywords: Mycobacterium tuberculosis; multidrug resistant TB; drug development; signal transduction pathways

Summary:

New Medicines for Tuberculosis (NM4TB) aims to develop successfully new drugs for the treatment of tuberculosis (TB) through an integrated approach implemented by a team, which combines some of Europe’s leading academic TB researchers with a major pharmaceutical company and three SMEs, all with a strong commitment to discovering new anti-infective agents. NM4TB has a comprehensive portfolio of potential and validated targets plus several novel proprietary anti-TB agents in its drug development pipeline. Among the validated targets are several enzymes involved in highly druggable areas such as cell wall biogenesis, nucleic acid synthesis and central metabolic pathways for which assays amenable to high-throughput screening are available. Intensive efforts will focus on rapidly emerging targets that impact upon two, as yet, untouched areas of the physiology of M. tuberculosis signal transduction pathways and persistence.

Background:

Tuberculosis (TB) is one of the oldest diseases known to man and has infected one third of the world’s population. As a result, someone dies from the disease every 15 seconds and 30 million more people will lose their lives to TB in the next decade. Although directly observed short-course chemotherapy is available to treat the disease, this treatment is old, slow and inefficient by the current standards of the pharmaceutical industry. Here the most innovative approaches will be employed to identify and validate targets for new drugs, and implement the screening and medicinal chemistry processes required to identify lead compounds for the generation of candidate drugs.

[+] Read More